Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR
暂无分享,去创建一个
C. Langebrake | F. Ayuk | C. Wolschke | R. Massoud | P. Freiberger | E. Klyuchnikov | Ulrike Bacher | A. Badbaran | N. Kröger | D. Janson | Adrin Dadkhah